132327-80-1

Basic information

• Product Name: Nalpha-Fmoc-Ndelta-trityl-L-glutamine
• Synonyms: N-ALPHA-9-FLUORENYLMETHOXYCARBONYL-N-GAMMA-TRITYL-GLUTAMINE;N-ALPHA-(9-FLUORENYLMETHOXYCARBONYL)-N-GAMMA-TRITYL-L-GLUTAMINE;N-ALPHA-9-FLUORENYLMETHOXYCARBONYL-N-OMEGA-TRITYL-L-GLUTAMINE;NALPHA-(9-FLUORENYLMETHOXYCARBONYL)-NR-TRITYL-GLUTAMINE;NA-FMOC-NG-TRITYL-L-GLUTAMINE;N-ALPHA-FMOC-N-DELTA-TRITYL-L-GLUTAMINE;N-ALPHA-FMOC-N-GAMMA-TRITYL-L-GLUTAMINE;N-ALPHA-FMOC-N-TRITYL-L-GLUTAMINE
• CAS NO: 132327-80-1
• Molecular Formula: C39H34N2O5
• Molecular Weight: 610.7
• EINECS: 1533716-785-6
• Product Categories: Fluorenes, Flurenones;Amino Acid Derivatives;Amino Acids;Glutamine [Gln, Q];Fmoc-Amino Acids and Derivatives;Fmoc-Amino acid series
• Mol File: 132327-80-1.mol
• Article Data: 10

Chemical Properties

• Melting Point: 165-172 °C
• Boiling Point: 873.5 °C at 760 mmHg
• Flash Point: 482.1 °C
• Appearance: White to yellow/Powder
• Density: 1.257 g/cm³
• Vapor Pressure: 1.29E-32mmHg at 25°C
• Refractive Index: 1.636
• Storage Temp.: 2-8°C
• PKA: 3.73±0.10(Predicted)
• Sensitive: Moisture Sensitive
• BRN: 4343953
• CAS DataBase Reference: Nalpha-Fmoc-Ndelta-trityl-L-glutamine(CAS DataBase Reference)
• NIST Chemistry Reference: Nalpha-Fmoc-Ndelta-trityl-L-glutamine(132327-80-1)
• EPA Substance Registry System: Nalpha-Fmoc-Ndelta-trityl-L-glutamine(132327-80-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-53-43
• Safety Statements: 22-24/25-26-61-37-24
• WGK Germany: 3
• F: 10-21
• Hazardous Substances Data: 132327-80-1(Hazardous Substances Data)

Usage

Chemical Properties

white to light yellow crystal powde

Uses

Fmoc-Gln(trt)-OH, is an amino acid derivative used in chemical synthesis and peptide chemistry.

General Description

Fmoc-Gln(Trt)-OH has good solubility properties in most organic solvents, and its use has been shown to result in significantly purer peptides than other derivatives used for the introduction of Gln [1]. Coupling can be performed by standard procedures. The trityl-protecting group is normally removed by 95% TFA in 1-3 hours, with no alkylation of Trp.The product number for this product was previously 04-12-1090.To obtain a certificate of analysis (CoA) of a lot that begins with the letter “A”, please select the option in the right hand menu “Request a COA for Lot#s starting with A”.

InChI:InChI=1/C39H34N2O5/c42-36(41-39(27-14-4-1-5-15-27,28-16-6-2-7-17-28)29-18-8-3-9-19-29)25-24-35(37(43)44)40-38(45)46-26-34-32-22-12-10-20-30(32)31-21-11-13-23-33(31)34/h1-23,34-35H,24-26H2,(H,40,45)(H,41,42)(H,43,44)/t35-/m1/s1

Upstream product

• 76-84-6 triphenylmethyl alcohol 
• 71989-20-3 N₂-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-glutamine 
• 132388-60-4 (S)-2-(((benzyloxy)carbonyl)amino)-5-oxo-5-(tritylamino)pentanoic acid 
• 2650-64-8 Cbz-L-Gln 
• 56-85-9 L-glutamine 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 102747-84-2 5-trityl-L-glutamine 
• 104-94-9 4-methoxy-aniline 
• 13152-84-6 2-chloroacenaphthylene-1-carbaldehyde 
• 132297-88-2 1-((p-methoxyphenyl)amino)-2-(((p-methoxyphenyl)imino)methyl)acenaphthylene hydrochloride 

Downstream Products

• 422309-19-1 7-(N^α-9-fluorenylmethoxycarbonyl-N^γ-trityl-L-glutamyl)amino-4-methylcoumarin 
• 326494-25-1 C₇₇H₁₂₉N₂₁O₂₂ 
• 406728-90-3 N-[Nα-(9-fluorenylmethoxycarbonyl)-Nδ-trityl-L-glutaminyl]-3-hydroxy-4-methoxyaniline 
• 1042435-58-4 C₁₀₂H₁₆₃N₂₅O₂₁ 
• 1042435-55-1 C₉₉H₁₆₀N₂₈O₂₁ 
• 1139906-53-8 C₁₁₃H₁₃₃N₁₃O₁₆ 
• 1139906-54-9 C₁₂₃H₁₅₀N₁₄O₂₁ 
• 1192494-10-2 [N-α-Fmoc-N-γ-(trityl)glutamyl]asparagyl-NH2 

Relevant articles and documents

Caged xanthones: Potent inhibitors of global predominant MRSA USA300

Total of 22 caged xanthones were subjected to susceptibility testing of global epidemic MRSA USA300. Natural morellic acid showed the strongest potency (MIC of 12.5 μM). However, its potent toxicity diminishes MRSA therapeutic potential. We synthetically modified natural morellic acid to yield 13 derivatives (3a-3m). Synthetically modified 3b retained strong potency in MRSA growth inhibition, yet the toxicity was 20-fold less than natural morellic acid, permitting the possibility of using caged xanthones for MRSA therapeutic.

NOVEL PEPTIDES DERIVED FROM NCAM (FGLs)

The present invention relates to novel compounds comprising at most 13 contiguous amino acid residues derived from the fibronectin type 3,I1 module of neural cell adhesion molecule (NCAM), or a variant or fragment thereof, capable of interacting with an FGFR and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to the use of said compounds for production of a medicament for treatment of conditions and diseases, wherein NCAM and/or FGFR play a prominent role.

GLP-2 compounds, formulations, and uses thereof

The present invention relates to novel human glucagon-like peptide-2 (GLP-2) peptides and human glucagon-like peptide-2 derivatives which have a protracted profile of action as well as polynucleotide constructs encoding such peptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.